Groundbreaking research reveals how common diabetes medications might offer unprecedented protection against heart attacks and strokes in survivors.

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

A new study finds SGLT2 inhibitors like Jardiance and GLP-1 drugs like Ozempic provide different benefits depending on the ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes remission compared with calorie restriction alone, according ...

Combined strategy is effective but questions remain The view that the hyperglycaemia associated with type 2 diabetes is ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Comparative ...

The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.